Genomics-driven immunoproteomics (GDI) is a platform that helps identify antigenic protein targets of mutations and other deoxyribonucleic acid (DNA) variations that are commonly associated with pathological states. This platform utilizes data generated from deep sequencing of exomic DNA or ribonucleic acid (RNA) as input to synthesize mutant peptides into microarrays, which then can be used to detect antigenic proteins that invoke immune response in patients. The technology has been used to detect antigenic targets of multiple sclerosis, an autoimmune disease [1], and cancer to identify mutant proteins that invoke immune response in breast cancer patients [2]. This technology has many potential applications to select genomic changes that are specifically recognized by the immune system in a rapid and efficient manner.
Rekombinante Antikörper: Lehrbuch und Kompendium für Studium und Praxis
Dübel, Stefan; Breitling, Frank; Frenzel, André; Jostock, Thomas; Marschall, Andrea L. J.; Schirrmann, Thomas; Hust, Michael
Jan 2019
Inmunotecnología y sus aplicaciones
Álvarez-Vallina, Luis; González Fernández, África; Magadán Mompó, Susana; Ramírez, Natalia; Reche, Pedro A; Toyos, J. R. de los; Ybarra, Gabriel
Jan 2018
High-Density Peptide Arrays for Malaria Vaccine Development
Loeffler, Felix F.; Pfeil, Johannes; Heiss, Kirsten
The development of an efficacious and practicable vaccine conferring sterile immunity towards a Plasmodium infection represents a not yet achieved goal. A crucial factor for the impact of a given anti-plasmodial subunit vaccine is the identification of the most potent parasitic components required to induce protection from both infection and disease. Here, we present a method based on a novel high-density peptide array technology that allows for a flexible readout of malaria antibodies. Peptide arrays applied as a screening method can be used to identify novel immunogenic antibody epitopes under a large number of potential antigens/peptides. Ultimately, discovered antigen candidates and/or epitope sequences can be translated into vaccine prototype design. The technology can be further utilized to unravel antibody-mediated immune responses (e.g., involved in the establishment of semi-immunity) and moreover to confirm vaccine potency during the process of clinical development by verifying the induced antibody responses following vaccination.
